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Abstract
Background: To investigate whether alterations in the developing intestinal microbiota and immune markers
precede celiac disease (CD) onset in infants at familial risk of developing the disease.
Methods: A nested case-control study was carried out as part of a larger prospective cohort study, which included
healthy full-term newborns (> 200) with at least one first relative with biopsy-verified CD. The present study
includes cases of CD (n = 10) and the best-matched controls (n = 10) who did not develop the disease after 5-year
follow-up. Fecal microbiota, assessed by high-throughput 16S rRNA gene amplicon sequencing, and immune
parameters were profiled at 4 and 6 months of age and related to CD onset.
Results: The microbiota of infants who remained healthy showed an increase in bacterial diversity over time,
characterized by increases in Firmicutes families, but not those who developed CD. Infants who subsequently
developed CD showed a significant reduction in sIgA levels over time, while those who remained healthy showed
increases in TNF-α correlated to Bifidobacterium spp. An increased relative abundance of Bifidobacterium longum
was associated with control children while increased proportions of Bifidobacterium breve and Enterococcus spp.
were associated with CD development.
Conclusion: The findings suggest that alterations in the early trajectory of gut microbiota in infants at CD risk could
influence the immune maturation process and predispose to CD, although larger population studies are warranted
to confirm this hypothesis.
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Background
Celiac disease (CD) is an immune-mediated systemic
disorder elicited by an aberrant response to dietary glu-
ten proteins found in wheat, rye, and barley, which de-
velops in genetically predisposed individuals [1]. The
disease is strongly associated with the human leukocyte
antigen HLA-DQA1 and HLA-DQB1 genes expressed as
surface heterodimers in antigen-presenting cells (APCs).
The majority of CD patients (95%) carry the HLA-
DQ2.5 heterodimer, while most of the remaining
patients have the HLA-DQ8 heterodimer [2]. Approxi-
mately 30–40% of the Caucasian subjects carry these risk
haplotypes but most of them do not develop the disease,
which has a prevalence rate of 1–3% in the general popu-
lation and up to 10% in first-degree relatives of CD pa-
tients [3, 4]. Therefore, the HLA-DQ2/DQ8 gene variants
are necessary but not sufficient for the disease to develop.
Although non-HLA variants also contribute to CD risk [4],
studies on the heritability of CD in twins indicate that
genetics alone cannot explain CD onset and that non-
shared environmental elements also contribute [5].
Gluten intake is the only environmental trigger of CD
with an established pathogenic role. APCs recognize glu-
ten peptides and activate lamina propria infiltrating T lym-
phocytes. This leads to the release of pro-inflammatory
cytokines, mainly interferon (IFN)γ and IL-15, activation
of cytotoxic T cells, and profound tissue damage [6, 7].
Exclusion of gluten from the diet is the only treatment
available, but adherence to a gluten-free diet (GFD) can be
difficult. Therefore, a better understanding of modifiable
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factors contributing to the breakdown of gluten tolerance
would be desirable to enable novel strategies for primary
prevention.
The timing of gluten introduction to the infant’s diet
may offer a window of opportunity for protection against
CD in predisposed individuals [8, 9]; however, it has not
proven effective in recent randomized intervention studies
(PreventCD and CELIPREV) [10, 11]. Epidemiological
data suggest that additional environmental factors, such as
type of delivery at birth, milk-feeding practices, intestinal
infections, and/or use of antibiotics, could also determine
CD risk [12–16]. A commonality of the aforementioned
factors is that they impact on gut microbiota and, thereby,
may influence its role in guiding the immune system to-
wards development, or not, of gluten tolerance [17].
Observational studies have reported alterations in the
composition of the microbiota of CD patients as well as
increased abundance of virulence-related genes in intes-
tinal pathobionts [18]. Furthermore, some authors re-
ported that some of these alterations are not due to
adherence to a GFD [19] and may be associated with
gastrointestinal symptoms in untreated CD [20] and GFD-
treated patients [21]. The contributing role of perturba-
tions in the gut microbiota, and of specific enteric bac-
teria, to gluten-induced immunopathology has been
proven in animal models [22]. Further evidence from lon-
gitudinal studies in human subjects is, however, needed to
elucidate the role of the gut microbiota in CD etiology.
With this aim, the prospective PROFICEL study enrolled
a cohort of newborn healthy infants at familial risk of de-
veloping CD to monitor the progressive assembly of gut
microbiota and its temporal relationship with factors po-
tentially contributing to CD risk. Initial studies in this co-
hort of infants showed that the intestinal microbiota is
influenced by both milk-feeding type and the HLA-DQ
genotype [23, 24].
Building upon these findings, the present study aimed
to investigate whether alterations in the developing in-
testinal microbiota and immune markers precede CD
onset in infants at familial risk of developing the disease.
The ultimate goal of the study is to shed light on the in-
teractions between modifiable environmental and herit-
able factors in CD with a view to helping progress
towards primary prevention.
Methods
Study design and follow-up
A nested case-control study was carried out as part of a
larger prospective cohort study (PROFICEL), which in-
cluded healthy full-term newborns with at least one first
relative with biopsy-verified CD. Enrollment lasted from
June 2006 to November 2010, as described elsewhere
[23]. The present study includes cases of CD (n = 10)
and the best-matched controls (n = 10) from the cohort
who did not develop the disease by the time of cases’
disease onset. Data regarding the mode of delivery, size,
weight, and weeks of gestation were recorded at birth
(Table 1). The health status, antibiotic intake, and feed-
ing habits (i.e., breastfeeding and formula feeding, intro-
duction of complementary foods) were monitored
during the study period (5 years).
A total of 18 fecal samples from 9 controls and 9 CD
cases were collected at 4 months, and a total number of
20 stool samples from 10 controls and 10 CD cases were
collected at 6 months and analyzed in the present study.
The DNA typing for CD HLA DQA1 and HLA DQB1
genes genotype was elucidated using sequence-specific
primers (PCR-SSP) [23]. The HLA-DQ genotyping allowed
the classification of the infants into three groups: the
group 1 (high risk) included those individuals carrying the
DQ2 haplotype in both cis (DQA1*05:01-DQB1*02:01 in
homozygosis) and trans conformations (DQA1*02:01-
DQB1*02:02 with DQA1*05:05-DQB1*03:01 in heterozy-
gosis), associated with the highest probability (20%) of
developing CD. The group 2 (intermediate risk) included
those infants carrying the DQ2 haplotype in cis conform-
ation along with any other haplotype, as well as infants
carrying the DQ8 haplotype (DQA1*03:01 DQB1*03:02)
in homozygosis. This genotype is associated with a 7%
probability of developing CD. The group 3 (low risk) in-
cluded those infants with other common genotypes not
associated with CD.
Ten infants were diagnosed with CD at the age shown
in Table 1. The disease was diagnosed according to the
1990 criteria of the European Society of Pedriatric Gastro-
enterology, Hepatology and Nutrition (ESPGHAN) based
on symptoms, positive anti-tissue transglutaminase (tTG)
antibodies, quantified using a tTG-IgA ELISA kit (Phar-
macia Diagnostics, GmbH), and the histologic analysis of
duodenal biopsy demonstrating villous atrophy compat-
ible with Marsh 3 classification. From the same cohort, a
subset of best-matched control children (n = 10) regarding
the type of delivery, HLA-DQ genotype, and type of feed-
ing were selected for comparative purposes. In both
groups, exclusion criteria included the onset of other dis-
orders related to immune dysregulation such as type-1
diabetes, allergies, and IgA deficiency.
Fecal sample processing
Fecal sample processing was done as described previ-
ously [24]. Briefly, fecal samples were diluted 1:10 (w/v)
with PBS (130 mM NaCl and 10 mM Na2HPO4, pH 7.4)
and homogenized. Aliquots submitted to low-spin cen-
trifugation (600g, 2 min, at 4 °C) were used for DNA ex-
traction (FastDNA™ SPIN kit for Soil, MP Biomedicals,
Santa Ana, CA, USA). Aliquots submitted to high-speed
centrifugation (15,000g, 10 min, at 4 °C) were used for
immune marker quantification.
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Immune marker quantification
Calprotectin was quantified by diluting fecal samples in
the calprotectin sample solution and using the ELISA
Quantitative Fecal Calprotectin kit (DIAsource, Louvain-
la-Neuve, Belgium). Secretory IgA (sIgA) and cytokines
(tumor necrosis factor (TNF)-α, interferon (IFN)-γ,
interleukin (IL)-1β and IL-6) were quantified using
ELISA commercial kits (Bethyl, Montgomery, TX, USA)
and Max Deluxe set (Biolegend, San Diego, CA, USA)
respectively. The threshold sensitivity level for sIgA was
7.8 ng/mL; for TNF-α, IFN-γ, and IL-6 was 7.8 pg/mL;
and for IL-1β was 2.0 pg/mL.
Sequencing of 16S rRNA gene amplicons
The V1-V2 variable region of the bacterial 16S rRNA
gene was amplified from the fecal DNA by PCR as de-
scribed previously [25] and sequenced using the Illumina
MiSeq platform (2 × 250 bp reads).
Sequence analysis
The 16S rRNA gene sequence data were processed using
the Mothur software package [26] as described previ-
ously [25]. After filtering to remove poor quality se-
quences and chimeras, each sample was rarefied to 2698
reads to ensure equal sequencing depth for all subse-
quent comparisons. Good’s coverage estimates at this se-
quencing depth averaged 99.6% (minimum of 99.2%).
Clusters were analyzed using the Jaccard calculator,
based on the presence/absence of operational taxonomic
units (OTUs), and the Bray-Curtis calculator, based
upon the presence/absence of OTUs and also on the
relative abundance of each OTU. Diversity indexes
(Shannon and inverse Simpson) were calculated using
Mothur. OTUs were classified taxonomically by match-
ing against the reference RDP database provided at the
Mothur website (https://www.mothur.org/wiki/RDP_re
ference_files#Version_10). Classification of selected
Table 1 Characteristics of the infants included in the study
ID Type of
delivery
aHLA-DQ
genotype
CD diagnosis
(months)
Gender Relatives
with CD
Gestation
(weeks)
Height (cm)
at birth
Weight (g)
at birth
Type of feeding
at 4 months
Type of feeding
at 6 months
Intake of
antibiotics
Controls
(n = 10)
C1 Vaginal 1 F Brother 40 52 3730 FF C + FF
C2 Vaginal 2 M Brother 40 51 3750 FF C + FF
C3 Vaginal 2 F Father 40 50 3335 BF C + BF
C4 Vaginal 1 F Mother 39 48 2960 BF C + FF + BF
C5 Cesarean 1 M Mother 38 50 2800 BF C + BF Clarithromycin
C6 Vaginal 2 F Mother 39 49 2900 FF C + FF
C7 Cesarean 2 M Sister 38 51 3190 BF C + FF + BF
C8 Vaginal 1 F Father 39 49 3890 BF C + BF
C9 Vaginal 2 F Bother 38 50 3610 BF C + BF
C10d Vaginal 3 M Mother 40 52 3880 BF C + BF
bMean (SE) 39.1 (0.3) 50.2 (0.42) 3405
(133.2)
CD cases
(n = 10)
CD1 Vaginal 1 40 F Mother 36 51 4890 FF C + FF
CD2 Vaginal 2 30 M Sister 40 50 3450 FF C + FF Augmentin
CD3 Vaginal 2 21 M Brother 37 48 3380 BF C + SM Amoxicillin
CD4 Vaginal 1 27 F Mother 38 48 3005 BF C + FF
CD5 Cesarean 1 16 F Sister 37 47 2730 BF C + FF Amoxicillin
CD6 Vaginal 2 26 F Mother 39 49 3200 FF C + FF Augmentin
CD7 Cesarean 1 36 F Mother 38 50 4360 BF C + BF
CD8 Vaginal 1 24 M Mother +
sister
41 50 4170 BF C + SM Augmentin
CD9 Vaginal 2 82 M Mother +
sister
37 48 3030 BF C + BF
CD10d Vaginal 2 40 F Mother 40 47 3070 BF C + BF
bMean (SE) 34.2 (5.9) 38.3 (0.5) 48.8 (0.44) 3529
(222.7)
cp value 1.000 0.828 – 1.000 0.258 0.190 0.033 0.6385 1.000 0.172 0.143
BF breastfeeding, FF formula feeding, C complementary feeding (foods other than milk and water), SM soya milk
aGenetic risk of developing CD was established according to the HLA-DQ genotype (see the “Methods” section for details)
bData of continuous variables are expressed as mean and standard error of the mean (in brackets)
cStatistically significant differences between cases and controls were established by applying using a t test for continuous variables and the chi-square test for
categorical variables at p < 0.050
dNo microbiota analysis available for these samples at 4 months
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OTUs was verified using MegaBLAST against the NCBI
database.
Statistical analyses
All data analyzed in this study are shown in
Additional files 1 and 2: Tables S1 and S2. Data distribu-
tion was assessed with the Shapiro-Wilk W test (SPSS
software V19). Of the demographic data, the categorical
variables were analyzed using the chi-square test
(GradPad, 6.0) and the continuous variables (size,
weight, and weeks of gestation at birth) using a t test
(SPSS software V19). Comparisons of data of immune
parameters between groups were done using the t test
for non-paired samples and within groups over time
were done using the t test for paired samples (SPSS soft-
ware V19). Compositional comparisons at the OTU,
genus, family, and phylum levels were carried out using
metastats [27] and LEfSe [28]. False discovery rate was
used for p value correction upon multiple comparisons
using the Benjamini-Hochberg method [29]. With meta-
stats, the relative abundance of each OTU was compared
across the two populations (CD and control) by comput-
ing a two-sample t statistic. The null distribution of t
was estimated non-parametrically using a permutation
test [27]. For diversity measures, the Mann Whitney U
test was used for comparisons between infant groups
and the Wilcoxon signed-rank test for comparisons
within groups at different ages using R v3.12. Correla-
tions between the microbiota composition and immuno-
logical parameters were established using the Spearman
coefficient (GradPad, 6.0). Statistically significant differ-
ences were established at p < 0.05.
Results
Demographic data, genetics, and early feeding pattern of
the infants
A nested case-control study was conducted to investi-
gate the role of the evolution of the infant gut micro-
biota in CD onset in a subset of subjects selected from a
larger prospective cohort study [23]. The Table 1 shows
the baseline characteristics of the infants included in the
study. These were similarly distributed between the two
groups (p < 0.05), except for height at birth, which was
higher in the controls than in the CD group (50.2 versus
48.8 cm, p < 0.05). Regarding the type of feeding, at
4 months of age, 3 subjects were fed with formula and 7
were breast-fed in both the control and CD group.
According to pediatricians’ recommendations, all infants
started the transition from milk feeding to the first solid
foods between 4 and 6 months of age. The introduction
of gluten was initiated from 6 months of age onwards in
all cases. From birth to 4 months of age, no infections or
antibiotic intake were registered. Up to 6 months, a total
of 6 infants suffered from infections during the time
frame of our study and were treated with antibiotics. In-
fant CD2 suffered from pharyngitis; CD3 suffered from
an upper respiratory tract infection; CD5 suffered from
otitis; CD6 and CD8 suffered from an upper respiratory
tract infection and also from otitis, and control C5
suffered from bronchitis. No significant differences
(p = 0.143) were detected between groups in the intake of
antibiotics.
The diagnosis of CD for most cases occurred between
the ages of 16–40 months (mean 34.2 months, SE 5.9),
with the exception of one case (CD9), who was diag-
nosed at 82 months of age. At the time of diagnosis, all
CD children had elevated levels of tTG antibodies and
the following symptomatology: four cases presented
diarrhea and abdominal distension, one constipation and
asthenia, and five had no symptoms.
Early evolution of gut microbiota in relation to CD
development
Overall cluster analysis of the 16S rRNA gene sequence
data, using either the Jaccard or the Bray-Curtis calcula-
tors, showed there was little distinct clustering of the
early microbiota profiles by disease status later in life
(Fig. 1). However, the parsimony test as implemented in
Mothur software [26] suggested that there was a border-
line significant difference in bacterial community mem-
bership (Jaccard) (p = 0.045), but not in the community
structure (Bray-Curtis) at 4 months of age between the
two groups of infants. This significance disappeared by
6 months (p = 0.640).
Compositional analysis revealed the presence of eight
phyla across the whole dataset, but only four of them
were above the mean value of 1% of the total number of
reads. The relative abundance of reads corresponding to
Bacteroidetes, Proteobacteria, Firmicutes, and Actinobac-
teria in the CD and control groups at 4 and 6 months
are represented in Fig. 2. At 4 months of age, children
that later developed CD harbored a significantly higher
proportion (p = 0.036) of Firmicutes compared to those
that remained healthy (control group). This generally
occurred alongside proportional reductions in Proteo-
bacteria and Bacteroidetes, although the differences in
these two phyla were not significant. At 6 months, no
differences at the phylum level were observed between
the two groups of children (Fig. 2).
We also evaluated the possible influence of covariates
on gut microbiota composition, which could bias the re-
sults of comparisons between infants that remained
healthy and those who developed CD later in life. No
differences (p > 0.05) depending on the HLA-DQ geno-
type (high risk versus intermediate risk), the type of milk
feeding (breast milk versus formula together or not with
complementary feeding), and the effect of antibiotic in-
take in the samples collected at 6 months of age (positive
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intake versus negative intake) were detected with meta-
stats after correcting for multiple comparisons.
The early microbiota of CD children and the control
group showed a different developmental process regarding
the relative abundance of Firmicutes. In control children,
Firmicutes proportions showed a statistically significant
increase from 4 to 6 months of age (p = 0.011), while in
the CD children, differences were not detected over time
(Fig. 2). At both 4 and 6 months, no differences were
observed between groups of children in the most abun-
dant bacterial families and genera. When considering the
gut microbiota development over time within groups,
children that remained healthy showed proportional
increases in Enterococcaceae (p = 0.030) (Fig. 3a) and in
Fig. 2 Proportion of the different phyla detected at 4 months (4M) and 6 months (6M) of age in children who developed celiac disease (CD
group, “CD”) and who remained healthy (control group, “C”). The phyla are represented with different colors indicating that they belong to
Bacteroidetes (yellow), Proteobacteria (red), Firmicutes (blue), and Actinobacteria (green)
Fig. 1 Jaccard dendrogram colored by disease status, with controls at 4 months (dark blue), controls at 6 months (light blue), and children who
developed CD (CD group) at 4 months (pink) and at 6 months (red)
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Peptostreptococcaceae (p = 0.020) (Fig. 3b) from 4 to
6 months of age, whereas no differences were found in the
CD group over time.
We also used the LEfSe software program to detect puta-
tive bacterial biomarker species that could predict later de-
velopment of CD [28]. At the level of the individual OTUs
(a total of 374—see Additional file 1: Table S1), LEfSe ana-
lyses indicated that increased relative abundance of Bifido-
bacterium longum was associated with the control group
(Linear Discriminant Analysis (LDA) = 5.004, p = 0.021),
while that of Bifidobacterium breve (LDA= 4.846, p = 0.032)
and Enterococcus spp. (Enterococcus gallinarum/casselifla-
vus/faecium, LDA= 4.507, p = 0.018) were associated with
the CD cases. The presence of Clostridium innocuum (LDA
= 4.005, p= 0.047), Veillonella dispar/parvula LDA= 3.867,
p = 0.009), and Intestinibacter bartlettii (LDA = 3.415,
p = 0.003) were associated with the age of 6 months.
Richness and diversity analyses
Microbial diversity was analyzed in both groups at 4 and
6 months (Fig. 4). The control group that remained
healthy showed a statistically significant increase in both
richness and diversity over the study period, as measured
by the number of observed OTUs (p = 0.024) (Fig. 4a), the
Shannon diversity index (p = 0.009) (Fig. 4b), and the in-
verse Simpson diversity index (p = 0.013) (Fig. 4c). In con-
trast, there was no significant increase in the microbial
diversity over the study period in the group of children
who developed CD later in life (p = 0.155, p = 0.193,
and p = 0.407, for comparisons of number of OTUs,
Shannon, and inverse Simpson indexes, respectively).
Quantification of immune markers
Children who developed CD showed a significant reduc-
tion (p = 0.037) in fecal sIgA levels from 4 to 6 months
of age, while the reductions did not reach statistical sig-
nificance in children that remained healthy (Fig. 5a). No
differences in the calprotectin levels were observed be-
tween groups at 4 months or 6 months or within groups
over the study period (Fig. 5b). There was huge variabil-
ity in calprotectin levels between individuals, which was
more pronounced in the case of the CD children. In this
group, the coefficient of variation (CV) was 85.0% at
4 months, and 103.2% at 6 months.
Regarding differences in cytokines, children who
developed CD had higher levels of intestinal IL-6 (p =
0.043) than the control group at 4 months, but this dif-
ference disappeared at 6 months (Fig. 6a). The concen-
tration of TNF-α tended to increase over time only in
control children (p = 0.051; Fig. 6b), which might be
linked to maturation of the gut microbiota and its in-
creased diversity. Comparisons between groups also re-
vealed that the control group showed higher TNF-α
levels than the CD group (p = 0.028) at 6 months
(Fig. 6b). No differences were observed in the IL-1β or
IFN-γ levels between or within groups (Fig. 6c, d).
At 4 months, sIgA concentrations were positively cor-
related with Bacteroidaceae (r = 0.778, p = 0.017) and En-
terobacteriaceae (r = 0.733, p = 0.031) and negatively
with Lachnospiraceae (r = − 0.895, p = 0.002) and Corio-
bacteriaceae (r = − 0.712, p = 0.037) in the control group.
Besides, a positive association was found between Firmi-
cutes and calprotectin (r = 0.857, p = 0.024). At 6 months,
the control group showed a positive correlation between
Bifidobacteriaceae and TNF-α (r = 0.730, p = 0.020) and
two negative ones between “unclassified Lachnospira-
ceae” and IFN-γ levels (r = − 0.644, p = 0.049) and
Bacteroidaceae and IFN-γ levels (r = − 0.831, p = 0.005).
This latter negative correlation was also found in the CD
group at the same time point (r = − 0.806, p = 0.007).
Discussion
This is the first study to identify features of the bacterial
community assembly and intestinal immune milieu that
a b
Fig. 3 a, b Significantly different families detected at 4 months (4M) and 6 months (6M) of age in children who developed celiac disease (CD
group) and who remained healthy (control group). Statistically significant differences were established at p ˂ 0.05. Red dots correspond to the
infants that were exposed to antibiotics from 4 to 6 months of age
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precede CD onset and that may constitute predictive
markers of disease risk and modifiable risk factors. Al-
though there were not great differences in microbiota
composition between the two infant groups (those who
later developed CD or those who remained healthy), spe-
cific differences were identified in the early evolution of
bacterial communities and of immune markers associ-
ated with subsequent CD development.
Our study shows a significant increase in microbiota
diversity of control children between the ages of 4 and
6 months, which did not occur in the child group who
went on to develop CD. Similarly, specific bacterial com-
munities followed a different trajectory over time in the
study groups, revealing differences in the phylum Firmi-
cutes, and the families Enterococcaceae and Peptostrepto-
coccaceae belonging to this phylum, whose proportions
increased from 4 to 6 months only in those children
who did not develop CD. Previous studies reported that
the phylogenetic diversity of the microbiota in the first
stages of life increases over time [30–32]. It was also es-
timated that the Gini-Simpson α-diversity index in-
creases by 0.008 per day on average during the first
month of life [33]. However, in the child group who
went on to develop CD, diversity did not increase signifi-
cantly over time, showing an uncommon developmental
pattern (“premature maturation”) compared to the
healthy group, since they started with a higher basal di-
versity level. Therefore, a progressive increase in micro-
bial diversity seems to be a feature of the evolution of a
healthy microbiota, which may increase resilience to
CD. A previous prospective study with only one case
developing CD at 24 months of age also reported re-
ductions in bacterial richness before disease onset (6 to
10 months of age) [34]. However, the findings of the
a b c
Fig. 4 Number of observed OTUs (a), Shannon (b), and the inverse Simpson (c) diversity indexes detected at 4 months (4M) and 6 months (6M)
of age in children who developed celiac disease (CD group) and who remained healthy (control group). Values are expressed as means and
standard error of means. Statistically significant differences were established at p < 0.05. Red dots correspond to the infants that were exposed to
antibiotics from 4 to 6 months of age
a b
Fig. 5 Secretory IgA (sIgA) (a) and calprotectin (b) in feces collected at 4 months (4M) and 6 months (6M) of age from children who developed celiac
disease (CD group) and who remained healthy (control group). Values are expressed as means and standard error of means. Statistically significant
differences were established at p < 0.05. Red dots correspond to the infants that were exposed to antibiotics from 4 to 6 months of age
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aforementioned study are of limited value since statis-
tical analysis could not be performed with a single CD
case. Furthermore, the results are incomparable since
the cited study aimed to investigate how CD onset was
affected by the time the gluten was introduced into the
diet, introducing different variables from those consid-
ered in our study.
A number of observational and to a lesser extent inter-
vention studies in adults have generally associated an
increased bacterial diversity with a healthy phenotype
[35–37]. The present study, however, suggests that a
timely maturation of the gut microbiota towards one of
higher complexity and diversity might also be required
for proper development of immune tolerance in the early
stages of life and that premature maturation and exposure
to a complex microbiota may increase disease risk.
In our study, a control group of infants matching the
disease group regarding the type of milk feeding, mode
of delivery, and the HLA genotype was selected for com-
parative purposes. Therefore, the early increase in diver-
sity observed in the infants who subsequently developed
CD could be due to other uncontrolled environmental
exposures that influence colonization waves of the in-
fant’s gut (perinatal factors, hospital and home environ-
ment, number of siblings, etc.) or additional genetic
factors that create permissive conditions to accommo-
date a more heterogeneous microbiota. Although the ef-
fect of host genetics on the microbiota is less known
than the effects of environmental factors, associations
between the microbiome and genes related to innate im-
munity that could control gut colonization (e.g., pattern
recognition receptors) have been identified through
genome-wide association studies [38].
Intestinal infections and their treatment with antibi-
otics have been associated with an increased risk of de-
veloping CD in some studies [13]. However, our study
infants only suffered from otitis and respiratory tract in-
fections during the study period and the antibiotic treat-
ment was not significantly associated with CD onset. A
possible impact of antibiotic intake on the microbiota of
our infants could not be completely disregarded due to
the relatively small size of the study. Nonetheless, the
microbiota of those infants who later developed CD
already presented a pattern of maturation significantly
different to the control group at 4 months of age (before
the intake of antibiotics), according to the differences in
the bacterial community membership (Jaccard similarity
index) that were attributed to increases in Firmicutes.
Taking into account the CD genetic risk classification
of the infants included in the study, we did not find
a b
c d
Fig. 6 Cytokine levels, interleukin (IL)-6 (a), tumor necrosis factor (TNF)-α (b), IL-1β (c), and interferon (IFN)-γ (d) in feces collected at 4 months
(4M) and 6 months (6M) of age from children who developed celiac disease (CD group) and who remained healthy (control group). Values are
expressed as means and standard error of means. Statistically significant differences were established at p < 0.05. Red dots correspond to the
infants that were exposed to antibiotics from 4 to 6 months of age
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significant association with the intestinal microbiota
composition either. These results are in agreement with
our previous studies reporting no major differences in
microbiota composition as a function of genotype when
comparing risk groups 1 and 2 by qPCR [23]. Notwith-
standing, we did find differences when comparing the
high-risk groups 1 and 2 with the low-genetic risk group
3 [23] and also when comparing the highest risk infants
(group 1) with low-risk infants (group 3) [24].
In our previous studies on CD, we found that the high-
risk genotype for developing CD was associated with
reduced numbers of Bifidobacterium (Actinobacteria
phylum), specifically of the species B. longum [23] com-
pared to the low-risk genotype. Accordingly, at that time,
we hypothesized that microbiota differences associated
with the HLA-DQ2/8 genotype could constitute an add-
itional risk factor for CD onset. The present results further
support the hypothesis that a reduced abundance of B.
longum, dependent on both genetic and environmental
factors, may constitute a risk factor for CD development
and constitute an early predictive biomarker of CD.
Our present study also suggests that early proportions
of Firmicutes and members of the Actinobacteria
phylum (B. longum) in infants at familial risk of develop-
ing CD are influenced not only by the HLA-DQ2/8
genotype [23], but also possibly by other genetic and en-
vironmental factors. However, considering the complex-
ity of the Firmicutes phylum, larger cohort sizes and in-
depth taxonomic studies will be needed to understand
the potential biological role played by specific compo-
nents of this phylum and their role in CD onset in re-
sponse to other environmental factors.
Interestingly, we also observed a faster reduction in
sIgA fecal levels in the children who went on to develop
CD over time compared to healthy ones. sIgA is gener-
ally considered to act as a first line of defense in the in-
testine by interacting with intestinal antigens and
microbes, preventing their penetration into the lamina
propria, and therefore contributing to immunological
homeostasis [39]. sIgA is also thought to play a role in
mucosal sensing and control of commensal bacteria col-
onizing the gut [40]. Besides, sIgA influences the devel-
opment of dendritic cells with a tolerogenic phenotype,
which play a key role in maintaining intestinal homeo-
stasis [41, 42]. Thus, it can be hypothesized that a pre-
mature reduction of sIgA levels in the group of children
that developed CD could be related to shifts in bacterial
community development which impact the maturation
of the mucosal immune functions, possibly increasing
the risk of developing autoimmune dysfunctions. More-
over, the fact that CD frequently occurs in subjects with
selective IgA deficiency has been interpreted as an indi-
cator that there is a reduction in the infant’s mucosal
protection [6].
The differential profiles of fecal cytokines over time in
the two groups of infants may also reflect differences in
gut microbiota maturation. Early increased levels of IL-6
could be related to premature maturation of the micro-
biota of infants who finally developed CD, while in-
creased levels of TNF-α at 6 months could reflect the
host response to a more diverse microbiota acquired at
this age by infants who remained healthy, and to its
specific components such as Bifidobacterium, which
showed a positive correlation with TNF-α.
The strength of this report lies in the exhaustive pro-
spective follow-up of the study cohort, where bias that
usually affects retrospective studies has been excluded.
Furthermore, a nested case-control study has integrated
genotypic, dietary, immune, and microbiota data from
biopsy-verified CD cases for the first time. The main limi-
tation is the relatively small population size of the pro-
spective study, taking into account the low prevalence of
CD in this at-risk population (~ 10%). This limits the stat-
istical power to investigate the effects of different covari-
ates, including the possible role of antibiotics, which
would have helped to reach more robust conclusions.
Conclusions
Overall, we demonstrate shifts in the early trajectory of
the gut microbiota along with changes in immune markers
in infants who later develop CD. These alterations are in-
dicative of deviations of the normal microbiota maturation
process, which precede CD development. Further studies
that build on these observations are warranted to progress
in the understanding of the specificities of these deviations
and the mechanisms by which they might increase disease
risk in response to environmental triggers.
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